Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, People's Republic of China.
Funct Integr Genomics. 2024 Aug 13;24(4):136. doi: 10.1007/s10142-024-01416-w.
Protein disulfide isomerase A3 (PDIA3) is an endoplasmic reticulum (ER) protein. It has different functions including glycoprotein folding in the ER. The unfavorable prognosis of cancer patients was related to the abnormal PDIA3 expression level. However, it is unclear how PDIA3 correlates with the malignant characteristics of different tumors and its impact on tumor immunity. Pan-cancer data were downloaded from several databases for large-scale bioinformatics analysis. The immunological functions of PDIA3 were systematically explored at the single-cell sequencing level, including cell communication, cell metabolism, cell evolution and epigenetic modification. We performed immunofluorescence staining to visualize PDIA3 expression and infiltration of macrophages in pan-cancer samples. Further, we performed a loss-of-function assay of PDIA3 in vitro. The CCK8 assay, clone formation assay, and transwell assay were performed. M2 macrophages were co-cultured with different cell lines before the transwell assay was performed. The immunofluorescence staining of pan-cancer samples presented a higher expression of PDIA3 than those of the paired normal tissues. According to single-cell sequencing analysis, expression of PDIA3 was closely associated with cell communication, cell metabolism, cell evolution and epigenetic modification. The knockdown of PDIA3 in tumor cells inhibited cell proliferation and invasion, and restrained cocultured M2 macrophage migration. Furthermore, PDIA3 displayed predictive value in immunotherapy response in human cancer cohorts, indicating a potential therapeutic target. Our study showed that PDIA3 was associated with tumor malignant characteristics and could mediate the migration of M2 macrophages in various tumor types. PDIA3 could be a promising target to achieve tumor control and improve the immune response on a pan-cancer scale.
蛋白质二硫键异构酶 A3(PDIA3)是一种内质网(ER)蛋白。它具有多种功能,包括 ER 中糖蛋白的折叠。癌症患者的不良预后与 PDIA3 表达水平异常有关。然而,PDIA3 如何与不同肿瘤的恶性特征相关及其对肿瘤免疫的影响尚不清楚。从多个数据库中下载泛癌症数据进行大规模生物信息学分析。在单细胞测序水平上系统地探讨了 PDIA3 的免疫功能,包括细胞通讯、细胞代谢、细胞进化和表观遗传修饰。我们进行了免疫荧光染色,以可视化泛癌症样本中 PDIA3 的表达和巨噬细胞的浸润。此外,我们在体外进行了 PDIA3 的功能丧失实验。进行了 CCK8 测定、克隆形成测定和 Transwell 测定。在进行 Transwell 测定之前,将 M2 巨噬细胞与不同细胞系共培养。泛癌症样本的免疫荧光染色显示 PDIA3 的表达高于配对的正常组织。根据单细胞测序分析,PDIA3 的表达与细胞通讯、细胞代谢、细胞进化和表观遗传修饰密切相关。肿瘤细胞中 PDIA3 的敲低抑制了细胞增殖和侵袭,并抑制了共培养的 M2 巨噬细胞迁移。此外,PDIA3 在人类癌症队列的免疫治疗反应中具有预测价值,表明其是一个潜在的治疗靶点。我们的研究表明,PDIA3 与肿瘤恶性特征相关,并可调节多种肿瘤类型中 M2 巨噬细胞的迁移。PDIA3 可能是一个有前途的靶点,可以实现泛癌症范围内的肿瘤控制和改善免疫反应。